7,630 Shares in Blueprint Medicines Corporation (NASDAQ:BPMC) Purchased by Crestwood Advisors Group LLC

Crestwood Advisors Group LLC acquired a new position in shares of Blueprint Medicines Corporation (NASDAQ:BPMC - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 7,630 shares of the biotechnology company's stock, valued at approximately $675,000.

Other hedge funds have also modified their holdings of the company. Headlands Technologies LLC purchased a new position in Blueprint Medicines in the fourth quarter worth approximately $65,000. Thematics Asset Management acquired a new stake in shares of Blueprint Medicines in the 4th quarter valued at $72,000. Covestor Ltd raised its holdings in shares of Blueprint Medicines by 62.7% in the 4th quarter. Covestor Ltd now owns 973 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 375 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Blueprint Medicines during the 4th quarter worth $106,000. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Blueprint Medicines during the fourth quarter worth $116,000.

Blueprint Medicines Price Performance

BPMC stock remained flat at $129.46 on Friday. The firm has a market capitalization of $8.36 billion, a price-to-earnings ratio of -52.41 and a beta of 0.89. The business's 50 day moving average price is $122.99 and its two-hundred day moving average price is $104.61. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 1.01. Blueprint Medicines Corporation has a twelve month low of $73.04 and a twelve month high of $129.65.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 27.70% and a negative return on equity of 64.60%. The business had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. During the same quarter in the prior year, the firm posted $1.40 earnings per share. The company's revenue for the quarter was up 55.5% compared to the same quarter last year. Research analysts expect that Blueprint Medicines Corporation will post -1.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on BPMC shares. JPMorgan Chase & Co. restated a "neutral" rating and issued a $129.00 price target (down from $130.00) on shares of Blueprint Medicines in a research note on Monday, June 2nd. Citizens Jmp downgraded Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a report on Tuesday, June 3rd. Citigroup raised Blueprint Medicines from a "strong sell" rating to a "hold" rating and raised their target price for the stock from $83.00 to $129.00 in a research report on Wednesday, June 4th. Needham & Company LLC cut Blueprint Medicines from a "buy" rating to a "hold" rating and set a $130.00 target price for the company. in a research note on Monday, June 2nd. Finally, Wall Street Zen upgraded shares of Blueprint Medicines to a "hold" rating in a research note on Friday, July 18th. Eighteen analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Blueprint Medicines currently has a consensus rating of "Hold" and an average price target of $128.25.

Insider Buying and Selling

In other news, Director Jeffrey W. Albers sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $101.14, for a total value of $505,700.00. Following the transaction, the director owned 146,630 shares of the company's stock, valued at approximately $14,830,158.20. The trade was a 3.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Percy H. Carter sold 1,051 shares of the company's stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $128.25, for a total value of $134,790.75. Following the sale, the insider owned 53,155 shares of the company's stock, valued at $6,817,128.75. This trade represents a 1.94% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,351 shares of company stock worth $1,384,244. Insiders own 4.21% of the company's stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.